-
2023-504263-16-00
5
2023-05-25
This is an extension study designed to provide continued treatment for
-
2024-513669-38-00
5
2023-05-17
Stroke, Ischemic, TIA, Cardiac Disease, Atherosclerosis, Myocardial In
-
2023-505040-19-00
4
2023-04-11
Non-seminomatous germ-cell tumors (including testis, retroperitoneal a
-
2022-500085-96-00
5
2023-03-31
Patients with gambling disorder or sexual addiction or food addiction
-
2024-513195-18-00
5
2023-03-27
Severe asthma
-
2024-517414-15-00
4
2023-01-25
ER positive HER2 negative breast cancer
-
2022-501335-16-00
10
2023-01-16
Interstitial lung disease
-
2024-514353-30-00
6
2022-11-25
Idiopathic retroperitoneal fibrosis
-
2024-514180-25-00
5
2022-11-21
unresectable or metastatic HER2+ colorectal cancer
-
2022-500197-34-01
4
2022-11-03
Megalencephaly-CApillary malformation Polymicrogyria syndrome
-
2023-503442-30-00
5
2022-10-14
Multiple Myeloma
-
2022-500643-20-00
4
2022-09-27
Patients with locally advanced, metastatic or unresectable hepatocellu
-
2024-511899-32-00
10
2022-08-31
Dermatomyositis; Baricitinib in patients with relapsing or naïve derma
-
2024-515945-40-00
10
2022-05-02
Non small cell lung cancer
-
2023-509496-16-00
4
2022-04-21
Advanced /metastatic sarcomas: undifferentiated pleomorphic sarcoma, o
-
2022-502425-18-00
5
2022-04-19
Adenocarcinoma of the prostate
-
2024-511609-44-00
10
2022-02-03
Rectum cancer
-
2024-513191-17-00
4
2022-02-03
autoimmune hemolytic anemia
-
2023-504166-37-00
4
2022-02-01
Advanced ovarian, tubal or peritoneal cancer.
-
2023-508594-84-00
4
2022-01-11
Metastatic pancreatic adenocarcinoma
-
2024-511001-28-00
4
2021-12-13
Neuroendocrine tumor
-
2023-504949-31-00
3
2021-12-01
Advanced or metastatic non-squamous non-small lung cancer (mNSCLC) wit
-
2024-513983-24-00
6
2021-10-29
Diabetic Macular Oedema
-
2024-514843-27-00
6
2021-10-11
Severe asthma